These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8797308)

  • 21. Pharmacokinetics and tolerability of prulifloxacin after single oral administration.
    Picollo R; Brion N; Gualano V; Millérioux L; Marchetti M; Rosignoli MT; Dionisio P
    Arzneimittelforschung; 2003; 53(3):201-5. PubMed ID: 12705176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
    Nakamura T; Shimizu C; Hirakawa K; Inui S; Okuda K; Nakata C; Fujimoto H; Okura H; Uemura Y; Takahashi H
    Jpn J Antibiot; 2009 Jun; 62(3):194-202. PubMed ID: 19882980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Single-dose toxicity studies of prulifloxacin (NM441) in mice, rats and dogs and the active metabolite (NM394) in rats].
    Shimazu H; Ishikawa Y; Nishiguchi Y; Yoshida M; Iwakura K; Sumi N; Shindo Y
    J Toxicol Sci; 1996 Jun; 21 Suppl 1():33-44. PubMed ID: 8709168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical studies on the treatment of Campylobacter enteritis--emergence of quinolone-resistant Campylobacter jejuni after treatment with new quinolones].
    Obana M; Matsuoka Y; Irimajiri S; Tonooka H
    Kansenshogaku Zasshi; 1992 Jul; 66(7):923-9. PubMed ID: 1431368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prulifloxacin. NAD-441A, NM 441, Quisnon.
    Drugs R D; 2002; 3(6):426-30. PubMed ID: 12516950
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacokinetics of prulifloxacin. 2nd communication: pharmacokinetics and effect on hepatic drug-metabolizing enzyme activities after repeated administration and transfer into fetus and milk after a single administration in rats.
    Okuyama Y; Momota K; Morino A
    Arzneimittelforschung; 1997 Mar; 47(3):285-92. PubMed ID: 9105547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations.
    Gorlero F; Lorenzi P; Rosignoli MT; Picollo R; Ruggieri A; Barattè S; Dionisio P
    Drugs R D; 2007; 8(6):373-81. PubMed ID: 17963428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients.
    Mikamo H; Kawazoe K; Izumi K; Ito K; Tamaya T
    Drugs; 1995; 49 Suppl 2():326-30. PubMed ID: 8549350
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of clinical efficacy of rokitamycin (RKM) and ofloxacin (OFLX) for the treatment of Campylobacter enteritis by a double-blind method. The Research Committee for the Effect of Rokitamycin, Research Group for Infectious Enteritis].
    Obana M; Tomizawa I; Takizawa Y; Nitta Y; Sagara H; Seo T; Sato J; Tsunoda T; Ota S; Machii A
    Kansenshogaku Zasshi; 1991 Sep; 65(9):1165-82. PubMed ID: 1761896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prulifloxacin.
    Keam SJ; Perry CM
    Drugs; 2004; 64(19):2221-34; discussion 2235-6. PubMed ID: 15456336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens.
    O'Hare MD; Felmingham D; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(4):253-7. PubMed ID: 2941257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
    Gualco L; Schito AM; Schito GC; Marchese A
    Int J Antimicrob Agents; 2007 Jun; 29(6):679-87. PubMed ID: 17363225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antibacterial activity of fosfomycin against the causative bacteria isolated from bacterial enteritis].
    Fukuyama M; Furuhata K; Oonaka K; Hara T; Sunakawa K
    Jpn J Antibiot; 2000 Jul; 53(7):522-31. PubMed ID: 11019386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis.
    Grassi C; Salvatori E; Rosignoli MT; Dionisio P;
    Respiration; 2002; 69(3):217-22. PubMed ID: 12097764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers.
    Nakashima M; Uematsu T; Kosuge K; Okuyama Y; Morino A; Ozaki M; Takebe Y
    J Clin Pharmacol; 1994 Sep; 34(9):930-7. PubMed ID: 7983237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Single and 4-week oral toxicity studies of prulifloxacin (NM441) in aged dogs].
    Ihara T; Akune A; Nakama K; Chihaya Y; Nagata R; Sumi N; Asaoka H; Shindo Y
    J Toxicol Sci; 1996 Jun; 21 Suppl 1():149-69. PubMed ID: 8709158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
    Montanari MP; Mingoia M; Varaldo PE
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3616-22. PubMed ID: 11709353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The current status of infectious enteritis in Japan--reports of the "Research Group for Infectious Enteric Diseases, Japan" in the last 5 years (1996-2000)].
    Obana M; Sagara H; Aoki T; Kim R; Takizawa Y; Tsunoda T; Irimajiri S; Yamashita K
    Kansenshogaku Zasshi; 2002 May; 76(5):355-68. PubMed ID: 12073571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.